CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran ...

Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid ...

Dear Dr. Roach: My husband recently passed away one week after his 80th birthday. According to his death certificate, he died of lung cancer (not a surprise) and chronic myelomonocytic leukemia (CMML) ...

Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With ...

DEAR DR. ROACH: My husband recently passed away one week after his 80th birthday. According to his death certificate, he died of lung cancer (not a surprise) and chronic myelomonocytic leukemia (CMML) ...

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008 Patients received 1 cycle of subcutaneous (SC) azacitidine (75 ...

Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, the inner part of the bone that makes ...

Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial of STX-0712 to ...